Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q1 2021 Earnings Presentation
18 slides from Q-linea Ab's earnings presentation, May 6, 2021
Slide 1: Presentation Q1(21)
Presentation Q1(21) Jonas Jarvius, CEO Anders Lundin, CFO/IR STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 1st quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 1st quarter Q-linea is developing disruptive solutions for faster Lead product ASTar® infectious disease diagnostics, first product targeting sepsis Introduction to the company 146 employees & consultants at first quarter
Slide 4: Sepsis – a global health crisis
Sepsis – a global health crisis Time to correct treatment critical for patient outcome 4
Slide 5: Why is improved infectious disease diagnostics important?
Why is improved infectious disease diagnostics important? Sepsis AMR Antimicrobial Resistance Leading cause of death in U.S. hospitals1) Has been presented as #1 hospitalization cost in the US with over $24bn “The biggest threat to mankind” yearly3) Rapid diagnostics would reduce Kills >500,000 peop
Slide 6: ASTar workflow vs current workflow
Up to 40 hours faster actionable results And requires minimal hands-on time DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood draw stain clean culture selection Determination (AST) Optimized Time to Blood bottle Rapid ID Overnight 0.5
Slide 7: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Easy to use Comprehensive • Fully automated • Large antibiotic panel • ~2 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additional • Results in ~6 hours samples (e.g. urine)
Slide 8: ASTar enables anyone at the lab to load sample anytime
ASTar enables anyone at the lab to load sample anytime Click “start” Scan barcode Add sample Load AST disc Add sample barcode Click “Start run” Source: Company information and webpage 8
Slide 9: Health economic benefits of 24 hour faster diagnostics
Health economic benefits of 24 hour faster diagnostics Less pressure for Cost savings Lower mortality resistance and superinfections Up to 25% Up to 40% ~$2,500 – $20,000 reduction of C. difficile lower mortality rates1) cost savings per patient3) infections2) ASTar can provide 24-40 hour faster dia
Slide 10: Key highlights first quarter
Key highlights first quarter Clinical study update Presented strong interim results from the CE-IVD study EA means giving the same The indicative results indicated performance well above result as the reference method on the concentration regulatory requirements for approval of antibiotics that kill
Slide 11: Key highlights first quarter
Key highlights first quarter Received first order from Thermo Fisher Scientific Value of first order > 8 million SEK Structure with 6-month binding orders Pre-payment for part of binding order Marketing message and material Q-linea and Thermo Fisher Scientific work closely together to prepare and fi
Slide 12: Key highlights after period end
Key highlights after period end Q-linea achieves CE-IVD for ASTar with excellent results FDA and ISO requirements1,2) The ASTar® Instrument and ASTar® BC G- Kit offer the broadest combination of antimicrobials and dilution ranges in a single Essential agreement = Same MIC value as reference analysis
Slide 13: Full speed ahead with commercial activities
Full speed ahead with commercial activities Strong interest from customers to evaluate ASTar Ongoing activities • Pre-market activities ongoing at full speed • Training of personnel ongoing • Marketing material in final preparation Staged launch for long-term success • First evaluation customers in
Slide 14: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea During first quarter we have seen slight effects of the Corona pandemic Q-linea has seen a slight increase in sickness absence, directly as well as indirectly and the employees, whose duties allow, work from home. So-far no major changes in timelines du
Slide 15: Income statement first quarter
Income statement first quarter Net sales in the first quarter amounted to SEK 0 million (0.2). Operating result totalled SEK -63.8 million (-55.9). The company reported a loss after tax of SEK -63.2 million (-56.0). Earnings per share, before and after dilution amounted to SEK -2.34 (-2.44). Figures
Slide 16: Balance sheet at the end of Q1
Balance sheet at the end of Q1 Cash and cash equivalents amounted to SEK 12.5 million (10.1) Short-term investments in fixed-income funds SEK 106,1 million (165,7) and the current portion of non-current assets (listed bonds) SEK 82.6 million (131.0). Non-current assets, listed bonds SEK 73.0 million
Slide 17: Cash flow statement first quarter
Cash flow statement first quarter Cash flow from operating activities SEK -56.1 million (-59.1). Decrease cash outflow from operating activities mainly due to an improvement in changes of the working capital that exceeded the larger operating result compared to the same quarter last year. Cash flow
Slide 18: Thank you
Thank you O-LINEA™* 18